

Heart Failure Severity and Quality of Warfarin Anticoagulation Control (From the WARCEF Trial)

Lee, Tetz C.; Qian, Min; Lip, Gregory; Di Tullio, Marco R.; Graham, Susan; Mann, Douglas L.; Nakanishi, Koki; Teerlink, John R.; Freudenberger, Ronald S.; Sacco, Ralph L.; Mohr, J. P.; Labovitz, Arthur J.; Ponikowski, Piotr; Lok, Dirk J.; Estol, Conrado J.; Anker, Stefan D.; Pullicino, Patrick M.; Buchsbaum, Richard; Levin, Bruce; Thompson, John L. P.

DOI:

[10.1016/j.amjcard.2018.05.024](https://doi.org/10.1016/j.amjcard.2018.05.024)

License:

Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

Document Version

Peer reviewed version

Citation for published version (Harvard):

Lee, TC, Qian, M, Lip, G, Di Tullio, MR, Graham, S, Mann, DL, Nakanishi, K, Teerlink, JR, Freudenberger, RS, Sacco, RL, Mohr, JP, Labovitz, AJ, Ponikowski, P, Lok, DJ, Estol, CJ, Anker, SD, Pullicino, PM, Buchsbaum, R, Levin, B, Thompson, JLP, Homma, S & Ye, S 2018, 'Heart Failure Severity and Quality of Warfarin Anticoagulation Control (From the WARCEF Trial)', *The American Journal of Cardiology*.
<https://doi.org/10.1016/j.amjcard.2018.05.024>

[Link to publication on Research at Birmingham portal](#)

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Heart Failure Severity and Quality of Warfarin Anticoagulation Control (From the WARCEF Trial)

Tetz C. Lee MD, MPH , Min Qian PhD , Gregory Y.H. Lip MD ,
Marco R. Di Tullio MD , Susan Graham MD ,
Douglas L. Mann MD , Koki Nakanishi MD, PhD ,
John R. Teerlink MD , Ronald S. Freudenberger MD ,
Ralph L. Sacco MD, MS , J.P. Mohr MD , Arthur J. Labovitz MD ,
Piotr Ponikowski MD, PhD , Dirk J. Lok MD , Conrado Estol MD ,
Stefan D. Anker MD, PhD , Patrick M Pullicino MD ,
Richard Buchsbaum , Bruce Levin PhD ,
John L.P. Thompson PhD , Shunichi Homma MD ,
Siqin Ye MD, MS , the WARCEF Investigators

PII: S0002-9149(18)31196-2
DOI: [10.1016/j.amjcard.2018.05.024](https://doi.org/10.1016/j.amjcard.2018.05.024)
Reference: AJC 23328

To appear in: *The American Journal of Cardiology*

Received date: 23 March 2018
Revised date: 7 May 2018
Accepted date: 7 May 2018

Please cite this article as: Tetz C. Lee MD, MPH , Min Qian PhD , Gregory Y.H. Lip MD , Marco R. Di Tullio MD , Susan Graham MD , Douglas L. Mann MD , Koki Nakanishi MD, PhD , John R. Teerlink MD , Ronald S. Freudenberger MD , Ralph L. Sacco MD, MS , J.P. Mohr MD , Arthur J. Labovitz MD , Piotr Ponikowski MD, PhD , Dirk J. Lok MD , Conrado Estol MD , Stefan D. Anker MD, PhD , Patrick M Pullicino MD , Richard Buchsbaum , Bruce Levin PhD , John L.P. Thompson PhD , Shunichi Homma MD , Siqin Ye MD, MS , the WARCEF Investigators, Heart Failure Severity and Quality of Warfarin Anticoagulation Control (From the WARCEF Trial), *The American Journal of Cardiology* (2018), doi: [10.1016/j.amjcard.2018.05.024](https://doi.org/10.1016/j.amjcard.2018.05.024)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Heart Failure Severity and Quality of Warfarin Anticoagulation Control (From the WARCEF Trial)

Tetz C. Lee, MD, MPH^a, Min Qian, PhD^a, Gregory Y.H. Lip, MD^b, Marco R. Di Tullio, MD^a, Susan Graham, MD^c, Douglas L. Mann, MD^d, Koki Nakanishi, MD, PhD^a, John R. Teerlink, MD^e, Ronald S. Freudenberger, MD^f, Ralph L. Sacco, MD, MS^g, J.P. Mohr, MD^a, Arthur J. Labovitz, MD^h, Piotr Ponikowski, MD, PhDⁱ, Dirk J. Lok, MD^j, Conrado Estol, MD^k, Stefan D. Anker, MD, PhD^{l,m}, Patrick M Pullicino, MDⁿ, Richard Buchsbaum^a, Bruce Levin, PhD^a, John L.P. Thompson, PhD^a, Shunichi Homma, MD^a, Siqin Ye, MD, MS^a for the WARCEF Investigators*.

Affiliations:

- Columbia University Irving Medical Center, New York, NY, USA.
- Institute of Cardiovascular Sciences, University of Birmingham, England, United Kingdom
- The State University of New York at Buffalo, Buffalo, NY, USA.
- Washington University School of Medicine, St. Louis, MO, USA.
- Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California San Francisco, San Francisco, CA, USA.
- Lehigh Valley Hospital, Allentown, PA, USA.
- The University of Miami, Miami, FL, USA.
- The University of South Florida, Tampa, FL, USA.
- Military Hospital, Wroclaw, Poland.
- Deventer Hospital, Deventer, the Netherlands.
- Neurological Center for Treatment and Rehabilitation, Buenos Aires, Argentina.
- Division of Cardiology and Metabolism, Department of Cardiology; and Berlin-Brandenburg Center for Regenerative Therapies; Deutsches Zentrum für Herz-Kreislauf-Forschung partner site Berlin; Charité Universitätsmedizin Berlin, Germany.
- Department of Cardiology and Pneumology, University Medicine Göttingen, Göttingen, Germany.
- Kent Institute of Medicine and Health Science, Canterbury, United Kingdom

The investigators in the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Study Group are listed in the Supplementary Appendix

Running head: HF and Quality of Warfarin Control

Corresponding Author:

Tetz C. Lee, MD, MPH | Columbia University Irving Medical Center
PH 9-206, 622 West 168th Street, New York, NY, 10032
Phone: +1-212-342-6037 Fax: +1-212-342-6051 E-mail: sl4190@columbia.edu

ABSTRACT

Previous studies among patients with atrial fibrillation showed that a history of heart failure (HF) could negatively impact anticoagulation quality, as measured by the average time in therapeutic range (TTR).

Whether additional markers of HF severity are associated with TTR has not been investigated thoroughly. We aimed to examine the potential role of HF severity in the quality of warfarin control among patients with HF with reduced ejection fraction. Data from the Warfarin vs. Aspirin in Reduced Cardiac Ejection Fraction Trial (WARCEF) were used to investigate the association between TTR and HF severity. Multivariable logistic regression models were used to examine the association of markers of HF severity, including New York Heart Association (NYHA) class, Minnesota Living with Heart Failure (MLWHF) score and frequency of HF hospitalization, with TTR $\geq 70\%$ (high TTR). We included 1 067 participants (high TTR, N=413; low TTR, N=654) in the analysis. In unadjusted analysis, patients with a high TTR were older and less likely to have had strokes or receive other antiplatelet agents. Those patients also had lower NYHA class, better MLWHF scores, greater 6-minute walk distance and lower frequency of HF hospitalizations. Multivariable analysis showed that NYHA class III/IV (OR:0.68 [95% confidence intervals:0.49 to 0.94]), each 10-point increase in MLWHF score (i.e. worse health-related quality of life) (OR: 0.92 [0.86 to 0.99]), and higher number of HF hospitalization per year (OR:0.45 [0.30 to 0.67]) were associated with decreased likelihood of having high TTR. In HF patients with systolic dysfunction, NYHA class III/IV, poor health-related quality of life and a higher rate of HF hospitalization were independently associated with suboptimal quality of warfarin anticoagulation control. These results affirm the need to assess the new approaches, such as direct oral anticoagulants, to prevent thromboembolism in this patient population.

Keywords: Heart Failure; Quality and Outcomes; Thrombosis; Warfarin

Both American^{1,2} and European³ guidelines for the management of heart failure (HF) recommend anticoagulation for select HF patients, such as those with atrial fibrillation (AF) to prevent thromboembolism. In this setting, warfarin remains a common choice for anticoagulation, necessitating periodic monitoring of the international normalized ratio (INR) to adjust dosage. In patients on warfarin,

high quality of anticoagulation, as measured by the average time in therapeutic range (TTR), is associated with less thromboembolic event such as stroke or myocardial infarction.^{4,5} Previously using the data of patients with HF with reduced ejection fraction (HFrEF) and sinus rhythm from the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial⁶, we have demonstrated that patients on warfarin with high TTR is associated with improved net clinical benefit compared both with patients on warfarin with low TTR and patients on aspirin only.⁷ Unlike patients with AF, however, knowledge who tend to have a better anticoagulation among HFrEF patients is limited despite of high incidence of thrombosis among this population. We therefore undertook the present analysis of HFrEF patients enrolled in the WARCEF trial⁶ to investigate the association between HF severity and TTR.

METHODS

The protocol of the randomized, double-blinded WARCEF trial (<http://www.ClinicalTrials.gov> Trial Reg no. NCT00041938) has been described previously.⁶ Briefly, participants with LVEF $\leq 35\%$ who were in sinus rhythm were randomized to receive warfarin or aspirin. Additional eligibility criteria included age ≥ 18 years old, having no contraindications to warfarin, having a modified Rankin score of ≤ 4 , and on evidence-based heart failure medications (beta-blocker, angiotensin-converting enzyme [ACE] inhibitor, or angiotensin II receptor blockers [ARB], or hydralazine and nitrates). Participants were excluded if they had a clear indication for warfarin or aspirin, or if they had a condition that conferred a high risk of cardiac embolism. A total of 2,305 participants (warfarin arm, N=1,142; aspirin arm, N=1,163) were randomized from 168 centers in 11 countries from October 2002 to January 2010. The mean follow-up time was 3.5 ± 1.8 years. Institutional Review Boards at the coordinating centers for all sites approved the study, and all participants provided informed consent.

For this analysis, we included participants from the warfarin arm of the WARCEF trial only. Of these, 75 were excluded because they either had follow-up time less than six weeks or had a continuous

interruption of warfarin therapy after six weeks and therefore had missing TTR throughout the study.

The final study sample thus included 1,067 participants.

Assessment of TTR in WARCEF participants was described previously^{6,7}. Briefly, we assumed that any change between two consecutive INR measurements takes place linearly over a 5-day period. For the time period between two consecutive INR measurements, we imputed INR backwards using the INR value of the second measurement until five days after the first measurement. Then we imputed the first five days using linear interpolation of these two INR values.⁸ As an example, if the measured INR was 1.0 on day 1 and 2.0 on day 10, the imputed INRs are 1.2, 1.4, 1.6, and 1.8 on day 2, 3, 4, and 5, respectively, and are 2.0 on days 6 to 9. A six-weeks initial titration phase is allowed. The TTR for each patient is the patient's percentage of time on warfarin for which the patient was in therapeutic range (INR of 2 to 3.5) from the 7th week to the end of follow-up. Based on the previous literature⁹, final TTR $\geq 70\%$ were defined as the high TTR group and the rest as the low TTR group.

For this analysis, we considered the rate of HF hospitalizations per year as a marker of HF severity. An independent end-point adjudication committee adjudicated all outcomes and major adverse events in WARCEF, and HF hospitalizations were defined as hospital admission for HF or hospitalization for which HF was a major contributing factor for admission and which met all of the following criteria: 1) signs and symptoms of HF on admission; 2) admission to the hospital for at least 24 hours, excluding time in an emergency room or observation unit; and 3) the use of intravenous diuretic, vasodilator, or inotropic therapy for the purposes of treating HF. We also considered New York Heart Association (NYHA) functional class as a measure of severity of HF symptoms and exercise capacity, as well as health-related quality of life measured by the Minnesota Living With Heart Failure (MLWHF) questionnaire, which has been shown to be a powerful predictor of morbidity and mortality among HF patients.¹⁰ MLWHF score was categorized in three groups (MLWHF score: 0–23, good; 24–45,

moderate; 45–105, poor quality of life)¹¹. Finally, we measured exercise capacity of the participants quantitatively by the distance walked in six minutes.

To address all possible associations between clinical variables and high TTR, we considered all baseline characteristics obtained in the trial (Table 1). Briefly, for independent variables, we included demographic characteristics such as age, sex, race/ethnicity, education, and clinical characteristics including vitals (height, weight, body mass index, systolic and diastolic blood pressure, pulse rate), life style risk factors (smoking status, alcohol consumption), comorbidities and past medical history, medications, laboratory data, and LV ejection fraction. The definitions of each variable were detailed elsewhere⁶.

Data analysis was conducted SAS software version 9.4 [SAS Institute Inc., Cary, NC]. Participants' characteristics are presented as the mean \pm standard deviation (SD) for continuous variables and as a proportion for categorical variables. These values were compared between high TTR group and low TTR group using a two-sample *t*-test for continuous variables and χ^2 test for categorical variables. Logistic regression models were used to assess the association between the high TTR and clinical/demographic variables. We also used restricted cubic splines in univariable models to check the potential nonlinear association between high TTR and each variable. In all models, the outcome was high TTR. The final multivariable model was built using forward-backward stepwise selection with entry and removal criteria of $p = 0.05$. Missing values of baseline variables were imputed using means for continuous variables and modal values for categorical variables. For all statistical analyses, a two-tailed $P < 0.05$ was considered significant.

RESULTS

For the 1,067 WARCEF participants on warfarin therapy included in this analysis, the mean TTR was 62.6%. INR values were below 2.0 for 27.1% of the total treatment time and above 3.5 for 10.3% of the total treatment time. The mean INR value during treatment was 2.5 ± 0.95 .

Table 1 presents the descriptive data categorized by $TTR \geq 70\%$ or not. The participants with high TTR were older, more likely to have a history of myocardial infarction, worse kidney function, higher pulse, better MLWHF score, longer distance walked in 6 minutes, and fewer HF hospitalization. These participants were less likely to have hypertension, history of stroke or transient ischemic attack, and to be on other antiplatelet agents.

Relations between HF severity and TTR are depicted in Figure 1. Those with higher rate of HF hospitalization were likely to have low TTR: the median TTR of 0, 0–1, and >1 HF hospitalization per year was 64.9, interquartile range (IQR) [42.7–80.3], 58.0 [31.0–73.3], and 35.2 [8.1–58.8], $p < 0.001$, respectively (Figure 1A). For NYHA class, the median TTR among participants with NYHA I/II and III/IV were 65.8, IQR [42.7–80.3] and 56.4 [33.1–73.7], $p < 0.001$, respectively (Figure 1B). Higher health-related quality of life was associated with higher TTR: the median TTR of good, moderate, poor quality of life was 68.8, IQR [48.7–82.7], 63.3 [44.5–77.4], and 52.0 [21.1–73.9], $p < 0.001$, respectively (Figure 1C).

In the multivariable model after the stepwise selection, we found a higher number of HF hospitalization per year, NYHA class III/IV, and each 10-point increase in MLWHF score were independently associated with decreased likelihood of having high $TTR \geq 70\%$. Other significant predictors of high TTR were location, older age, race/ethnicity, greater weight, smoking status and other antiplatelet medications (as detailed in Table 2).

DISCUSSION

The present study demonstrated for the first time that markers of HF severity are associated with TTR. In our analysis of patients with HFrEF and sinus rhythm enrolled in WARCEF, HF severity were associated with the quality of anticoagulation independent of other important clinical factors. Our results suggest that for patients with HF being considered for warfarin therapy, those with more advanced HF may have more difficulty in achieving high quality of anticoagulation.

Although warfarin titration in HF patients is known to be challenging^{12,13}, there are several potential mechanisms for why HF severity may be an important risk factor for suboptimal TTR. It is possible that patients with more severe HF may have poorer adherence to taking warfarin or to follow-ups for INR.¹⁴ It is also possible that fluctuating volume status with intermittent volume overload from HF can affect intestinal absorption¹⁵ and metabolism of warfarin. For example, HF induced malabsorption of vitamin K or insufficient intake of vitamin K may predispose patients taking warfarin to INR elevations.¹⁶ Likewise, liver impairment due to congestive HF¹⁷ may interact warfarin response because the hepatic enzyme is responsible for oxidative metabolism of warfarin¹⁸, while also leading to insufficient production of clotting factors and platelets. There may also be an interaction between cardiovascular comorbidities and genetic determinants of warfarin metabolism, such as CYP2C9 and VKORC1 mutations.¹⁹⁻²¹ Further research is needed to clarify these mechanisms.

Previous studies have examined the factors affecting quality of warfarin anticoagulation in patients with AF²²⁻²⁶ and identified that the patients with HF were less likely to achieve target INR range.^{22,24} For instance, the SAME-TT₂R₂²² score was developed from the cohort of the AFFIRM (AF Follow-up Investigation of Rhythm Management) trial and externally validated in prospectively recruited 286 patients. They identified following factors were associated with suboptimal warfarin anticoagulation: female, less than 60 years of age, history of comorbidities such as hypertension, diabetes, coronary artery disease, peripheral arterial disease, congestive HF, stroke, pulmonary disease, liver or renal

disease, medications which have interaction with warfarin such as amiodarone, tobacco use within 2 years and non-white race. Although mixed results have been observed in other studies²²⁻²⁶, younger age, female, and non-white race/ethnicity were consistently associated with unfavorable INR control. Our findings are broadly similar. In our analysis, we confirmed that younger age and non-Hispanic black race/ethnicity were associated with low TTR. Although the specific mechanism of association between older age and warfarin control is unknown, a possible explanation is that older patients tend to have higher medication adherence than younger patients.²⁷ In contrast to previous studies, female sex was not independently associated with quality of anticoagulation control in our analysis, possibly due to the modest number of female participants in the WARCEF trial (approximately 20%).

For specific HF patients, such as those with AF or with a high risk for cardioembolism, both American and European current guidelines recommend anticoagulation to prevent thromboembolism.¹⁻³ Although not directly addressed by our analysis, we suspect that predictors of suboptimal TTR would be similar to patients with HFrEF who have other indications for anticoagulation. Identifying such patients may be useful to determine the optimal target population for the use of direct oral anticoagulants (DOACs) as DOACs have favorable risk-benefit profiles.²⁸ Given that optimal warfarin anticoagulation may be difficult to achieve especially in patients with more severe HF, our results also affirms the need to assess the effect of DOACs in this population, such as through the ongoing COMMANDER HF trial, which seeks to assess the effectiveness and safety of rivaroxaban in reducing the risk of death, myocardial infarction or stroke in participants with HF and coronary artery disease following an episode of decompensated HF (<https://ClinicalTrials.gov/show/NCT01877915>).

There are several limitations to address. First, the cross-sectional design of our study limits causal inference for the relationship between the quality of anticoagulation and HF severity. Second, we could not exclude the possibility that a hereditary predisposition contributed to warfarin resistance because we

did not collect the information about genetic polymorphisms. However, the previous randomized trial has shown that baseline genetic testing on sensitivity to warfarin does not affect clinically important outcomes²⁹. Third, the generalizability of our study might be limited because the WARCEF population included only HFrEF patients in sinus rhythm. While we expect similar mechanisms to be at play for HF patients in general, generalizability to HFrEF patients with AF will need to be validated in future studies. Fourth, the standard of care for HF during the WARCEF trial may differ from contemporary practice. It is reassuring that background pharmacological therapy for WARCEF participants are largely similar to the current era though angiotensin receptor-neprilysin inhibitor was not yet available as a treatment option, with >98%, 90%, 60% of patients receiving an ACE inhibitor or ARB, a beta-blocker, or a mineralocorticoid receptor antagonist, respectively. However, potential confounding may remain from unmeasured differences in how heart failure or anticoagulation were managed during the WARCEF era compared to the current one. Fifth, we did not measure the severity of HF by using existing risk scores such the MAGGIC Risk Score³⁰, as we did not capture the data elements necessary to calculate such scores.

In conclusion, a higher rate of HF hospitalizations, NYHA class III/IV, and poor quality of life were independently associated with suboptimal warfarin anticoagulation control among HF patients with reduced ejection fraction. These results affirm the need to assess the new approaches, such as direct oral anticoagulants, to prevent thromboembolism in this patient population.

ACKNOWLEDGMENT

The WARCEF trial was supported by grants (U01-NS-043975 [to Dr. Homma], U01-NS-039143 [to Dr. Thompson]) from the National Institute of Neurological Disorders and Stroke. Dr. Ye is supported by a NIH K23 career development award (K23-HL-121144). Dr. Lee is supported by a grant from the Abe Fellowship Program administered by the Social Science Research Council and in cooperation with and with funds provided by the Japan Foundation Center for Global Partnership.

Conflict of interest

Dr. Anker reports consultancy for Janssen (minor) - steering committee for COMMANDER-HF. Dr. Homma reports being a consultant for St. Jude Medical, Daiichi-Sankyo, Bristol Meyers Squibb, Pfizer. Dr. Labovitz has received a research grant from Bristol-Myers Squibb/Pfizer for the AREST trial. Dr. Lip has served as a consultant for Bayer, Astellas, Merck, AstraZeneca, Sanofi, BMS/Pfizer, Biotronik, Portola, and Boehringer Ingelheim and has been on the speakers bureau for Bayer, BMS/Pfizer, Boehringer Ingelheim, and Sanofi-Aventis. Dr. Sacco has received research grants from NINDS, NCATS, AHA, Evelyn McKnight Brain Foundation and Boehringer Ingelheim. Dr. Teerlink has received consulting fees/ research grants from Actelion, Amgen, Bayer, Cytokinetics, Medtronic, Novartis, St. Jude, Trevena. The other authors have no relationships to report.

References

1. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *Circulation* 2017;136:e137-161.
2. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL, American College of Cardiology Foundation/American Heart Association Task Force on Practice G. 2013

ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. *Circulation* 2013;128:e240-327.

3. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors/Task Force M. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2016;37:2129-2200.

4. Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P, Bankhead C, Xu Y. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. *Circ Cardiovasc Qual Outcomes* 2008;1:84-91.

5. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, Healey JS, Yusuf S, Investigators AW. Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range. *Circulation* 2008;118:2029-2037.

6. Homma S, Thompson JL, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR, Ammon SE, Graham S, Sacco RL, Mann DL, Mohr JP, Massie BM, Labovitz AJ, Anker SD, Lok DJ, Ponikowski P, Estol CJ, Lip GY, Di Tullio MR, Sanford AR, Mejia V, Gabriel AP, del Valle ML, Buchsbaum R, Investigators W. Warfarin and aspirin in patients with heart failure and sinus rhythm. *N Engl J Med* 2012;366:1859-1869.

7. Homma S, Thompson JL, Qian M, Ye S, Di Tullio MR, Lip GY, Mann DL, Sacco RL, Levin B, Pullicino PM, Freudenberger RS, Teerlink JR, Graham S, Mohr JP, Labovitz AJ, Buchsbaum R, Estol CJ, Lok DJ, Ponikowski P, Anker SD, Investigators W. Quality of anticoagulation control in preventing adverse events in patients with heart failure in sinus rhythm: Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial substudy. *Circ Heart Fail* 2015;8:504-509.
8. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. *Thromb Haemost* 1993;69:236-239.
9. Phillips KW, Ansell J. Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management. *Expert Rev Cardiovasc Ther* 2008;6:57-70.
10. Rodriguez-Artalejo F, Guallar-Castillon P, Pascual CR, Otero CM, Montes AO, Garcia AN, Conthe P, Chiva MO, Banegas JR, Herrera MC. Health-related quality of life as a predictor of hospital readmission and death among patients with heart failure. *Arch Intern Med* 2005;165:1274-1279.
11. Behloul H, Feldman DE, Ducharme A, Frenette M, Giannetti N, Grondin F, Michel C, Sheppard R, Pilote L. Identifying relative cut-off scores with neural networks for interpretation of the Minnesota Living with Heart Failure questionnaire. *Conf Proc IEEE Eng Med Biol Soc* 2009;2009:6242-6246.
12. Witt DM, Delate T, Clark NP, Martell C, Tran T, Crowther MA, Garcia DA, Ageno W, Hylek EM, Warped C. Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users. *J Thromb Haemost* 2010;8:744-749.
13. Nelson WW, Desai S, Damaraju CV, Lu L, Fields LE, Wildgoose P, Schein JR. International normalized ratio stabilization in newly initiated warfarin patients with nonvalvular atrial fibrillation. *Curr Med Res Opin* 2014;30:2437-2442.

14. Wu JR, Moser DK, Chung ML, Lennie TA. Predictors of medication adherence using a multidimensional adherence model in patients with heart failure. *J Card Fail* 2008;14:603-614.
15. Sandek A, Bauditz J, Swidsinski A, Buhner S, Weber-Eibel J, von Haehling S, Schroedl W, Karhausen T, Doehner W, Rauchhaus M, Poole-Wilson P, Volk HD, Lochs H, Anker SD. Altered intestinal function in patients with chronic heart failure. *J Am Coll Cardiol* 2007;50:1561-1569.
16. Greenblatt DJ, von Moltke LL. Interaction of warfarin with drugs, natural substances, and foods. *J Clin Pharmacol* 2005;45:127-132.
17. Allen LA, Felker GM, Pocock S, McMurray JJ, Pfeffer MA, Swedberg K, Wang D, Yusuf S, Michelson EL, Granger CB, Investigators C. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. *Eur J Heart Fail* 2009;11:170-177.
18. O'Reilly RA. Vitamin K and the oral anticoagulant drugs. *Annu Rev Med* 1976;27:245-261.
19. Muszkat M, Blotnik S, Elami A, Krasilnikov I, Caraco Y. Warfarin metabolism and anticoagulant effect: A prospective, observational study of the impact of CYP2C9 genetic polymorphism in the presence of drug-disease and drug-drug interactions. *Clinical Therapeutics* 2007;29:427-437.
20. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW. Identification of the gene for vitamin K epoxide reductase. *Nature* 2004;427:541-544.
21. Du J, Zhang Z, Ge Y, Zhen J, Leng J, Wang J. VKORC1 and CD-14 genetic polymorphisms associate with susceptibility to cardiovascular and cerebrovascular diseases. *Int J Clin Exp Med* 2015;8:20444-20453.

22. Apostolakis S, Sullivan RM, Olshansky B, Lip G. Factors Affecting Quality of Anticoagulation Control Among Patients With Atrial Fibrillation on Warfarin The SAME-TT2R2 Score. *Chest* 2013;144:1555-1563.
23. Shen AY, Yao JF, Brar SS, Jorgensen MB, Wang X, Chen W. Racial/Ethnic differences in ischemic stroke rates and the efficacy of warfarin among patients with atrial fibrillation. *Stroke* 2008;39:2736-2743.
24. Rose AJ, Ozonoff A, Henault LE, Hylek EM. Warfarin for atrial fibrillation in community-based practise. *J Thromb Haemost* 2008;6:1647-1654.
25. Birman-Deych E, Radford MJ, Nilasena DS, Gage BF. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. *Stroke* 2006;37:1070-1074.
26. White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, Albers GW. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. *Arch Intern Med* 2007;167:239-245.
27. Krueger K, Botermann L, Schorr SG, Griesse-Mammen N, Laufs U, Schulz M. Age-related medication adherence in patients with chronic heart failure: A systematic literature review. *International Journal of Cardiology* 2015;184:728-735.
28. Ferreira JP, Girel N, Alshalash S, Konstam MA, Zannad F. Antithrombotic therapy in heart failure patients with and without atrial fibrillation: update and future challenges. *Eur Heart J* 2016;37:2455-2464.

29. Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, Rosenberg YD, Eby CS, Madigan RA, McBane RB, Abdel-Rahman SZ, Stevens SM, Yale S, Mohler ER, 3rd, Fang MC, Shah V, Horenstein RB, Limdi NA, Muldowney JA, 3rd, Gujral J, Delafontaine P, Desnick RJ, Ortel TL, Billett HH, Pendleton RC, Geller NL, Halperin JL, Goldhaber SZ, Caldwell MD, Califf RM, Ellenberg JH, Investigators C. A pharmacogenetic versus a clinical algorithm for warfarin dosing. *N Engl J Med* 2013;369:2283-2293.
30. Pocock SJ, Ariti CA, McMurray JJ, Maggioni A, Kober L, Squire IB, Swedberg K, Dobson J, Poppe KK, Whalley GA, Doughty RN, Meta-Analysis Global Group in Chronic Heart F. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. *Eur Heart J* 2013;34:1404-1413.

Figure legends

Figure 1.

Heart Failure severity and quality of warfarin anticoagulation

A. Average number of HF hospitalization per year B. NYHA class C. Health-related quality of life
HF, heart failure; TTR, time in therapeutic range; NYHA, New York Heart Association; MLWHF score,

Minnesota Living with Heart Failure score.

Quality of warfarin anticoagulation was measured by the average time in therapeutic range (TTR). Health-related quality of life was measured by Minnesota Living with Heart Failure (MLWHF) score. MLWHF score was categorized in three groups (MLWHF score: 0–23, good; 24–45, moderate; 45–105, poor health-related quality of life).




Table 1. Participants characteristics by time in therapeutic range

| Variables | Time in therapeutic range $\geq 70\%$ (n=413) | Time in therapeutic range $< 70\%$ (n=654) | p-value |
|--------------------|---|--|---------|
| | | | |
| Location | | | <0.001 |
| Argentina | 16/413 (3.9%) | 23/654 (3.5%) | . |
| Europe | 226/413 (54.7%) | 271/654 (41.4%) | . |
| North America | 171/413 (41.4%) | 360/654 (55.0%) | . |
| Age (years) | 62.8 \pm 11.1 | 59.4 \pm 11.7 | <0.001 |
| Men | 337/413 (81.6%) | 509/654 (77.8%) | 0.139 |
| Non-Hispanic white | 356/413 (86.2%) | 453/654 (69.3%) | <0.001 |
| Non-Hispanic black | 21/413 (5.1%) | 128/654 (19.6%) | . |
| Hispanic | 27/413 (6.5%) | 54/654 (8.3%) | . |
| Other | 9/413 (2.2%) | 19/654 (2.9%) | . |
| Educational level | | | 0.281 |
| < High school | 187/413 (45.3%) | 268/654 (41.0%) | . |
| High school + | 165/413 (40.0%) | 293/654 (44.8%) | . |
| College + | 61/413 (14.8%) | 93/654 (14.2%) | . |

| | | | |
|--------------------------------------|-----------------|-----------------|-------|
| Height (cm) | 172.0±9.0 | 171.3±9.4 | 0.254 |
| Weight (kg) | 86.1±19.0 | 85.5±20.3 | 0.658 |
| Systolic blood pressure (mmHg) | 123.2±17.9 | 124.2±20.0 | 0.398 |
| Diastolic blood pressure (mmHg) | 73.3±11.3 | 74.4±11.7 | 0.133 |
| Pulse (beats/min) | 70.6±11.2 | 72.7±11.6 | 0.003 |
| Body-mass index (kg/m ²) | 29.0±5.5 | 29.0±6.3 | 0.891 |
| Smoking status | | | 0.001 |
| Current | 59/412 (14.3%) | 147/653 (22.5%) | . |
| Former | 234/412 (56.8%) | 304/653 (46.6%) | . |
| Never | 119/412 (28.9%) | 202/653 (30.9%) | . |
| Alcohol Consumption (oz/day) | | | 0.110 |
| Current, >2 | 106/413 (25.7%) | 156/654 (23.9%) | . |
| Previous, >2 | 76/413 (18.4%) | 156/654 (23.9%) | . |
| Never | 231/413 (55.9%) | 342/654 (52.3%) | . |
| Hypertension | 215/397 (54.2%) | 405/634 (63.9%) | 0.002 |
| Prior stroke or TIA | 42/412 (10.2%) | 98/653 (15.0%) | 0.024 |
| Atrial Fibrillation | 15/412 (3.6%) | 21/654 (3.2%) | 0.705 |
| Myocardial Infarction | 222/412 (53.9%) | 291/653 (44.6%) | 0.003 |
| Diabetes Mellitus | 131/412 (31.8%) | 216/653 (33.1%) | 0.664 |

| | | | |
|--|-----------------|-----------------|--------|
| Ischemic Cardiomyopathy | 193/412 (46.8%) | 262/653 (40.1%) | 0.031 |
| Peripheral Vascular Disease | 47/413 (11.4%) | 83/654 (12.7%) | 0.524 |
| Living with ICD | 73/412 (17.7%) | 119/654 (18.2%) | 0.843 |
| Hematocrit (%) | 41.9±4.1 | 41.6±4.7 | 0.330 |
| eGFR (mL/min/1.73 m ²) | 66.3±19.9 | 69.3±21.3 | 0.018 |
| Left ventricular ejection fraction (%) | 24.8±7.2 | 24.5±7.7 | 0.525 |
| NYHA class | | | 0.002 |
| I | 64/411 (15.6%) | 76/653 (11.6%) | . |
| II | 245/411 (59.6%) | 342/653 (52.4%) | . |
| III | 98/411 (23.8%) | 224/653 (34.3%) | . |
| IV | 4/411 (1.0%) | 11/653 (1.7%) | . |
| Baseline MLWHF score | 29.0±21.2 | 37.7±24.8 | <0.001 |
| Distance covered on 6-minute walk (meters) | 362.9±145.2 | 334.2±139.4 | 0.002 |
| Average number of HF hospitalization per year | 0.2±0.7 | 0.6±1.4 | <0.001 |
| Aspirin | 220/388 (56.7%) | 353/596 (59.2%) | 0.432 |
| Other antiplatelet agent | 6/173 (3.5%) | 23/228 (10.1%) | 0.011 |
| ACE Inhibitor | 344/412 (83.5%) | 556/652 (85.3%) | 0.433 |

| | | | |
|--|-----------------|-----------------|-------|
| ARB | 72/412 (17.5%) | 100/652 (15.3%) | 0.356 |
| Beta-blocker | 374/412 (90.8%) | 588/652 (90.2%) | 0.749 |
| Calcium-channel blocker | 33/412 (8.0%) | 58/652 (8.9%) | 0.615 |
| Diuretic | 322/412 (78.2%) | 542/652 (83.1%) | 0.043 |
| Statin | 264/322 (82.0%) | 385/456 (84.4%) | 0.367 |
| Aldosterone blocker | 148/252 (58.7%) | 241/381 (63.3%) | 0.252 |
| <p>TIA, temporary ischemic attack; ICD, implantable cardioverter–defibrillator; ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; NYHA, New York Heart Association; MLWHF, Minnesota Living With Heart Failure; HF, heart failure.</p> | | | |

Table 2. Association between time in therapeutic range ≥ 70 % and clinical factors

| | For a | Univariable model | | Multivariable model | |
|--------------------|-----------|---------------------|---------|----------------------|---------|
| Variables | change of | OR (95% CI) | p-value | OR (95% CI) | p-value |
| Location | | | | | |
| Argentina | | reference | < 0.001 | reference | 0.007 |
| Europe | | 1.2 (0.62,2.32) | | 0.82 (0.30,2.25) | |
| North America | | 0.68 (0.35,1.33) | | 0.52 (0.20,1.37) | |
| Age (years) | 10 | 1.30 (1.16,1.45) | < 0.001 | 1.28 (1.12, 1.46) | < 0.001 |
| Men | | 1.26 (0.93,1.72) | 0.139 | | |
| Non-Hispanic white | | reference | < 0.001 | reference | < 0.001 |
| Hispanic | | 0.64 (0.39,1.03) | | 0.6 (0.29,1.25) | |
| Non-Hispanic black | | 0.21 (0.13,0.34) | | 0.3 (0.18,0.51) | |

| | | | | | |
|----------------------------|----|---------------------|-------|----------------------|-------|
| Other | | 0.6 (0.27,1.35) | | 0.6 (0.26,1.40) | |
| Educational level | | | | | |
| < High school | | reference | 0.282 | reference | |
| High school + | | 0.81 (0.62,1.05) | | | |
| College + | | 0.94 (0.65,1.37) | | | |
| Height (cm) | | 1.01 (0.99,1.02) | 0.254 | | |
| Weight (kg, Linear Spline) | | | | | |
| < 72.7 | | 1.43 (1.08,1.89) | 0.041 | | |
| > 72.7 | | 0.95 (0.88,1.03) | | | |
| Weight (kg) | 10 | 1.01 (0.95,1.08) | 0.657 | 1.12 (1.04,1.21) | 0.004 |
| Systolic BP (mmHg) | 10 | 0.97 (0.91,1.03) | 0.397 | 0.91 (0.85, 0.98) | 0.015 |
| Diastolic BP (mmHg) | 10 | 0.92 (0.83,1.03) | 0.133 | | |

| | | | | |
|---|---------------------|-------|---------------------|-------|
| Pulse (beats/minutes) | 0.98 (0.97,0.99) | 0.003 | | |
| Body-mass index (kg/m ² , Linear Spline) | | | | |
| < 25.1 | 1.15 (1.04,1.27) | 0.019 | | |
| > 25.1 | 0.98 (0.95,1.00) | | | |
| Body-mass index (kg/m ²) | 1.00 (0.98,1.02) | 0.892 | | |
| Smoking status | | | | |
| Never | reference | 0.001 | reference | 0.013 |
| Current | 0.68 (0.47,0.99) | | 0.77 (0.51,1.16) | |
| Former | 1.31 (0.99,1.74) | | 1.32 (0.97,1.79) | |
| Alcohol consumption (oz/day) | | | | |
| Never | reference | 0.111 | | |
| Current, >2 | 1.01 (0.75,1.36) | | | |

| | | |
|--------------------------------|---------------------|-------|
| Previous, >2 | 0.72 (0.52,0.99) | |
| Hypertension | 0.68 (0.53,0.88) | 0.003 |
| Prior stroke or TIA | 0.64 (0.44,0.94) | 0.024 |
| Atrial Fibrillation | 1.14 (0.58,2.23) | 0.711 |
| Myocardial Infarction | 1.45 (1.13,1.86) | 0.003 |
| Diabetes Mellitus | 0.94 (0.72,1.23) | 0.657 |
| Ischemic Cardiomyopathy | 1.31 (1.02,1.68) | 0.032 |
| Peripheral Vascular Disease | 0.88 (0.60,1.29) | 0.524 |
| Living with ICD | 0.97 (0.70,1.33) | 0.829 |
| Hematocrit (% , Linear Spline) | | |
| < 39.2 | 1.12 (1.03,1.21) | 0.030 |

| | | | | | |
|--------------------------------------|----|-----------------|---------|-------------|---------|
| > 39.2 | | 0.97 | | | |
| | | (0.93,1.02) | | | |
| Hematocrit (%) | | 1.01 | 0.328 | | |
| | | (0.99,1.04) | | | |
| eGFR (mL/min/1.73 m ²) | | 0.99 | 0.019 | | |
| | | (0.99,1.00) | | | |
| LV ejection fraction (%) | | 1.01 | 0.525 | | |
| | | (0.99,1.02) | | | |
| NYHA class III or IV | | 0.58 | < 0.001 | 0.68 | 0.020 |
| | | (0.44,0.77) | | (0.49,0.94) | |
| Baseline MLWHF score (points) | 10 | 0.85 | < 0.001 | 0.92 (0.86, | 0.017 |
| | | (0.80,0.90) | | 0.99) | |
| Distance covered on 6-minute walk | 30 | 1.04 | 0.002 | | |
| (meters) | | (1.02,1.07) | | | |
| Average number of HF hospitalization | | 0.72 | < 0.001 | 0.45 | < 0.001 |
| per year | | (0.61,0.84) | | (0.30,0.67) | |
| Aspirin | | 0.86 | 0.250 | | |
| | | (0.67,1.11) | | | |
| Other antiplatelet agent | | 0.4 (0.16,1.00) | 0.050 | 0.33 | 0.025 |
| | | | | (0.13,0.87) | |

| | | |
|-------------------------|---------------------|-------|
| ACE Inhibitor | 0.87 (0.62,1.22) | 0.431 |
| ARB | 1.17 (0.84,1.63) | 0.354 |
| Beta-blocker | 1.07 (0.70,1.63) | 0.752 |
| Calcium-channel blocker | 0.89 (0.57,1.39) | 0.617 |
| Diuretic | 0.73 (0.53,0.99) | 0.043 |
| Statin | 0.75 (0.51,1.08) | 0.121 |
| Aldosterone blocker | 0.81 (0.61,1.08) | 0.153 |

OR, odds ratio; CI, confidence interval; TIA, temporary ischemic attack; ICD, implantable cardioverter–defibrillator; ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; eGFR, estimated glomerular filtration rate; LV, left ventricular; BP, blood pressure; NYHA, New York Heart Association; MLWHF, Minnesota Living With Heart Failure; HF, heart failure.

The final multivariable model was built using forward-backward stepwise selection with entry and removal criteria of $p=0.05$.